drugset
drugset / Trial / NCT02494505

Interest of Mycophenolate for CIDP Weaning

NCT02494505 ↗

Phase 3 Completed 40 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective is to study if the mycophenolate could decrease the proportion of patients who relapse during the IVIG tapering period and after the IVIG withdrawal.

Timeline

Start
2013-11-18
Primary completion
2018-05-09
Completion
2018-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 2 g Oral

Indications

chronic inflammatory demyelinating polyradiculoneuropathy